Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

207 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Lost to follow-up: a challenge over 10 years.
Poliseno M, Bavaro DF, Di Gennaro F, De Vita G, Girardi E, Saracino A, Monno L, Angarano G, Lo Caputo S. Poliseno M, et al. Among authors: lo caputo s. AIDS Care. 2021 Dec;33(12):1621-1626. doi: 10.1080/09540121.2020.1852159. Epub 2020 Nov 26. AIDS Care. 2021. PMID: 33242983
Ocular manifestations in HIV-seropositive patients.
Balacco Gabrieli C, Angarano G, Moramarco A, LoCaputo S, Castellano L. Balacco Gabrieli C, et al. Ann Ophthalmol. 1990 May;22(5):173-6. Ann Ophthalmol. 1990. PMID: 1973340
[Retinal lesions in HIV seropositive patients].
Gabrieli CB, Angarano G, Moramarco A, Locaputo S, Rasi V, Pacella E. Gabrieli CB, et al. J Fr Ophtalmol. 1989;12(8-9):521-4. J Fr Ophtalmol. 1989. PMID: 2635196 French.
Real versus virtual phenotype to guide treatment in heavily pretreated patients: 48-week follow-up of the Genotipo-Fenotipo di Resistenza (GenPheRex) trial.
Mazzotta F, Lo Caputo S, Torti C, Tinelli C, Pierotti P, Castelli F, Lazzarin A, Angarano G, Maserati R, Gianotti N, Ladisa N, Quiros-Roldan E, Rinehart AR, Carosi G; Genotipo-Fenotipo di Resistenza (GenPheRex) Group of the Italian Management Standardizzato di Terapia Antiretrovirale (MASTER) Cohort. Mazzotta F, et al. Among authors: lo caputo s. J Acquir Immune Defic Syndr. 2003 Mar 1;32(3):268-80. doi: 10.1097/00126334-200303010-00005. J Acquir Immune Defic Syndr. 2003. PMID: 12626886 Clinical Trial.
HIV-1 resistance to dideoxynucleoside reverse transcriptase inhibitors: genotypic-phenotypic correlations.
Torti C, Quiros-Roldan E, Monno L, Patroni A, Saracino A, Angarano G, Tinelli C, Mazzotta F, Lo Caputo S, Pierotti P, Carosi G; GenPheRex PhenGen Study Groups of the MASTER Cohort. Torti C, et al. Among authors: lo caputo s. J Acquir Immune Defic Syndr. 2004 Aug 15;36(5):1104-7. doi: 10.1097/00126334-200408150-00016. J Acquir Immune Defic Syndr. 2004. PMID: 15247566 Clinical Trial. No abstract available.
Drug resistance mutations and newly recognized treatment-related substitutions in the HIV-1 protease gene: prevalence and associations with drug exposure and real or virtual phenotypic resistance to protease inhibitors in two clinical cohorts of antiretroviral experienced patients.
Torti C, Quiros-Roldan E, Monno L, Patroni A, Saracino A, Angarano G, Tinelli C, Lo Caputo S, Tirelli V, Mazzotta F, Carosi G; MASTER Cohort GenPheRex Study Group; MASTER Cohort PhenGen Study Group. Torti C, et al. Among authors: lo caputo s. J Med Virol. 2004 Sep;74(1):29-33. doi: 10.1002/jmv.20142. J Med Virol. 2004. PMID: 15258965
Selection of antiretroviral therapy guided by genotypic or phenotypic resistance testing: an open-label, randomized, multicenter study (PhenGen).
Saracino A, Monno L, Locaputo S, Torti C, Scudeller L, Ladisa N, Antinori A, Sighinolfi L, Chirianni A, Mazzotta F, Carosi G, Angarano G. Saracino A, et al. J Acquir Immune Defic Syndr. 2004 Dec 15;37(5):1587-98. doi: 10.1097/00126334-200412150-00011. J Acquir Immune Defic Syndr. 2004. PMID: 15577415 Clinical Trial.
207 results